Fig. 6

3D185 significantly inhibited MC38 tumor growth in vivo and remodeled the tumor microenvironment. a Antitumor efficacy of 3D185 in MC38 models. Tumor growth inhibition of the treatment with 3D185 is shown. The RTVs are presented as the mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001, as determined by one-way ANOVA with Tukey’s multiple-comparison test. b-g Flow cytometric analysis of immune subsets in the MC38 tumor model treated with vehicle or the indicated inhibitor. Tumor tissues collected 2 h after treatment with 3D185. The infiltration of TAMs (b), CSF-1R⁺ TAMs (c), Treg (f),TNF-α⁺ CD8⁺ T cells (g) and IFN-γ⁺ CD8⁺ T cells (h) and the expression of CD206 (d) and CD86 (e) on TAMs were tested (n = 6 mice per group). Representative data from three independent experiments are shown. Data are shown as the mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001 vs the vehicle group, determined by one-way ANOVA with Dunnett’s multiple-comparison test. i IHC evaluation of CD31expression was performed on tumors from the MC38 tumor model after treatment with 3D185 (scale bar, 100 μm)